Betta Pharmaceuticals and Mankind Pharma reach exclusive licensing agreement for Ensartinib
India, Nov. 19 -- Delhi-based Mankind Pharma has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China's National Medical Products Administration (NMPA).
The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
Under the terms of the license agreement, Mankind Pharma will pay Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India. Mankind Pharma will be granted...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.